Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 Pathology, Chemoprevention, and Preclinical Models for Target Validation in Barrett Esophagus.Cancer Research.  78:3747-3754. 2018
2018 Myeloid-Derived Suppressor Cells Impair B Cell Responses in Lung Cancer through IL-7 and STAT5.Journal of Immunology.  201:278-295. 2018
2017 Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma.Blood Advances.  1:2375-2385. 2017
2017 Effects of Cellular Methylation on Transgene Expression and Site-Specific Integration of Adeno-Associated Virus.Genes.  8. 2017
2017 Silencing of TGF-β1 in tumor cells impacts MMP-9 in tumor microenvironment.Scientific Reports.  7:8678. 2017
2017 Osteoclast proton pump regulator Atp6v1c1 enhances breast cancer growth by activating the mTORC1 pathway and bone metastasis by increasing V-ATPase activity.Oncotarget.  8:47675-47690. 2017
2017 Resveratrol induces mitochondria-mediated, caspase-independent apoptosis in murine prostate cancer cells.Oncotarget.  8:20895-20908. 2017
2017 Location of tumor affects local and distant immune cell type and number.Immunity, Inflammation and Disease.  5:85-94. 2017
2017 Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stress.Federation proceedings.  31:1608-1619. 2017
2016 Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment.Oncotarget.  7:75407-75424. 2016
2016 Immature myeloid cells are critical for enhancing bone fracture healing through angiogenic cascade.BONE.  93:113-124. 2016
2016 Prostate cancer-derived cathelicidin-related antimicrobial peptide facilitates macrophage differentiation and polarization of immature myeloid progenitors to protumorigenic macrophages.Prostate.  76:624-636. 2016
2015 SOCS3 Deficiency in Myeloid Cells Promotes Tumor Development: Involvement of STAT3 Activation and Myeloid-Derived Suppressor Cells.Cancer Immunology Research.  3:727-740. 2015
2015 Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies.Cell Growth and Differentiation.  13:819-827. 2015
2015 Endostatin: A novel inhibitor of androgen receptor function in prostate cancer.Proceedings of the National Academy of Sciences.  112:1392-1397. 2015
2014 Anterior gradient protein-2 is a regulator of cellular adhesion in prostate cancer.PLoS ONE.  9:e89940. 2014
2014 Detection of Merkel cell polyomavirus in formalin-fixed, paraffin-embedded tissue of Merkel cell carcinoma and correlation with prognosis.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.  55:1057-1062. 2014
2014 The dual targeting of immunosuppressive cells and oxidants promotes effector and memory T-cell functions against lung cancer.OncoImmunology.  3:e27401. 2014
2013 Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways.Cancer Research.  73:6609-6620. 2013
2013 Myeloid-derived suppressor cells as osteoclast progenitors: a novel target for controlling osteolytic bone metastasis.Cancer Research.  73:4606-4610. 2013
2013 Myeloid-derived suppressor cells as a novel target for the control of osteolytic bone disease.OncoImmunology.  2:e24064. 2013
2013 Muscle-directed anti-Aβ single-chain antibody delivery via AAV1 reduces cerebral Aβ load in an Alzheimer's disease mouse model.Journal of Molecular Neuroscience.  49:277-288. 2013
2013 Polyglutamate directed coupling of bioactive peptides for the delivery of osteoinductive signals on allograft bone.Biomaterials.  34:1506-1513. 2013
2013 Role of plasmacytoid dendritic cells in breast cancer bone dissemination.OncoImmunology.  2:e22983. 2013
2013 Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer.Cancer Research.  73:672-682. 2013
2012 Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells.Journal of Immunology.  189:4258-4265. 2012
2012 Bone healing by endogenous stem cell mobilizationBONE.  51:635. 2012
2012 Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice.Cancer Immunology, Immunotherapy.  61:1441-1450. 2012
2012 Noggin is novel inducer of mesenchymal stem cell adipogenesis: implications for bone health and obesity.Journal of Biological Chemistry.  287:12241-12249. 2012
2012 Mobilization of bone marrow mesenchymal stem cells in vivo augments bone healing in a mouse model of segmental bone defect.BONE.  50:1012-1018. 2012
2011 Inhibition and promotion of tumor growth with adeno-associated virus carcinoembryonic antigen vaccine and Toll-like receptor agonists.Cancer Gene Therapy.  18:850-858. 2011
2011 LL-37 as a therapeutic target for late stage prostate cancer.Prostate.  71:659-670. 2011
2011 Conditionally replicating adenovirus expressing TIMP2 for ovarian cancer therapy.Clinical Cancer Research.  17:538-549. 2011
2011 Anti-Amyloid-β Single-Chain Antibody Brain Delivery Via AAV Reduces Amyloid Load But May Increase Cerebral Hemorrhages in an Alzheimer's Disease Mouse Model.Journal of Alzheimer's Disease.  27:23-38. 2011
2011 Conditionally replicating adenovirus expressing TIMP2 increases survival in a mouse model of disseminated ovarian cancer.PLoS ONE.  6:e25131. 2011
2010 Bacteriophage hyaluronidase effectively inhibits growth, migration and invasion by disrupting hyaluronan-mediated Erk1/2 activation and RhoA expression in human breast carcinoma cells.Cancer Letters.  298:238-249. 2010
2010 Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists.Vaccine.  28:7837-7843. 2010
2010 Merkel cell carcinoma: correlation of KIT expression with survival and evaluation of KIT gene mutational status.Human Pathology.  41:1405-1412. 2010
2010 Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton.Journal of Cellular Biochemistry.  111:249-257. 2010
2010 Mesenchymal stem cells expressing osteogenic and angiogenic factors synergistically enhance bone formation in a mouse model of segmental bone defect.Molecular Therapy.  18:1026-1034. 2010
2010 Therapeutic potential of genetically modified adult stem cells for osteopenia.Gene Therapy.  17:105-116. 2010
2009 Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasis.Clinical Cancer Research.  15:7175-7185. 2009
2009 Free fatty acids enhance breast cancer cell migration through plasminogen activator inhibitor-1 and SMAD4.Laboratory Investigation.  89:1221-1228. 2009
2009 Tumoristatic effects of endostatin in prostate cancer is dependent on androgen receptor status.Prostate.  69:1055-1066. 2009
2009 Detection of Merkel cell polyomavirus in formalin-fixed, paraffin-embedded tissue of Merkel cell carcinoma and its correlation with prognosis.Journal of Clinical Oncology.  27:6027. 2009
2009 High Cks1 expression in transgenic and carcinogen-initiated mammary tumors is not always accompanied by reduction in p27Kip1.International Journal of Oncology.  34:1425-1431. 2009
2009 Pulmonary angiogenesis in a rat model of hepatopulmonary syndrome.Gastroenterology.  136:1070-1080. 2009
2008 Genetic modification of adeno-associated viral vector type 2 capsid enhances gene transfer efficiency in polarized human airway epithelial cells.Human Gene Therapy.  19:1407-1414. 2008
2008 Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model.Gene Therapy.  15:1446-1453. 2008
2008 Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model.STEM CELLS.  26:2332-2338. 2008
2008 Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.Clinical Cancer Research.  14:4961-4970. 2008
2008 Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo.Clinical Cancer Research.  14:4971-4980. 2008
2008 Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis.Molecular Therapy.  16:871-878. 2008
2008 Therapeutic potential of genetically modified mesenchymal stem cells.Gene Therapy.  15:711-715. 2008
2008 Clinical significance of a novel single nucleotide polymorphism in the 5' untranslated region of the Rabphillin-3A-Like gene in colorectal adenocarcinoma.Frontiers in Bioscience.  13:1050-1061. 2008
2007 Bone homing of mesenchymal stem cells by ectopic alpha 4 integrin expression.Federation proceedings.  21:3917-3927. 2007
2007 Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model.Cancer Research.  67:5789-5797. 2007
2007 Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus.Gene Therapy.  14:627-637. 2007
2007 Notch1 augments intracellular trafficking of adeno-associated virus type 2.Journal of Virology.  81:2069-2073. 2007
2007 Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway.Gene Therapy.  14:138-146. 2007
2006 Airway epithelium directed gene therapy for cystic fibrosis.Medicinal Chemistry.  2:499-503. 2006
2006 Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease.Neurobiology of Disease.  23:502-511. 2006
2006 Activators of viral gene expression in polarized epithelial monolayers identified by rapid-throughput drug screening.Gene Therapy.  13:781-788. 2006
2006 Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands.Gene Therapy.  13:29-39. 2006
2005 Determination of osteoprogenitor-specific promoter activity in mouse mesenchymal stem cells by recombinant adeno-associated virus transduction.BBA - Biochimica et Biophysica Acta.  1731:95-103. 2005
2005 Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma.Cancer Research.  65:10041-10049. 2005
2005 Genomic stability of self-complementary adeno-associated virus 2 during early stages of transduction in mouse muscle in vivo.Human Gene Therapy.  16:1047-1057. 2005
2005 Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer.Clinical Cancer Research.  11:1342-1347. 2005
2005 Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor.Cancer Gene Therapy.  12:26-34. 2005
2004 Osteogenic differentiation of recombinant adeno-associated virus 2-transduced murine mesenchymal stem cells and development of an immunocompetent mouse model for ex vivo osteoporosis gene therapy.Human Gene Therapy.  15:1197-1206. 2004
2004 Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvant.Human Gene Therapy.  15:856-864. 2004
2004 Gene therapy for osteoinduction.Current Gene Therapy.  4:287-296. 2004
2004 Anti-angiogenic gene therapy for cancer (review).International Journal of Oncology.  25:335-343. 2004
2004 Detection of disseminated breast cancer growth and treatment response using non-invasive bioluminescence imaging.Journal of Clinical Oncology.  22:742. 2004
2004 Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor.Cancer Research.  64:1781-1787. 2004
2004 Delivery of DNA to tumor cells in vivo using adeno-associated virus.Methods in Molecular Biology.  246:237-243. 2004
2004 Parvovirus vectors for cancer gene therapy.Expert Opinion on Biological Therapy.  4:53-64. 2004
2002 Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands.Journal of Virology.  76:12900-12907. 2002
2002 Adenoassociated virus vectors for genetic immunization.Immunologic Research.  26:247-253. 2002
2001 Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy.Journal of Virology.  75:9493-9501. 2001
2001 Adeno-associated virus for cancer gene therapy.Cancer Research.  61:6313-6321. 2001
1999 Adeno-associated virus 2-mediated transduction and erythroid lineage-restricted expression from parvovirus B19p6 promoter in primary human hematopoietic progenitor cells.Journal of Hematotherapy.  8:585-592. 1999
1998 Adeno-associated virus type 2-mediated gene transfer: role of epidermal growth factor receptor protein tyrosine kinase in transgene expression.Journal of Virology.  72:9835-9843. 1998
1998 Characterization of wild-type adeno-associated virus type 2-like particles generated during recombinant viral vector production and strategies for their elimination.Journal of Virology.  72:5472-5480. 1998
1998 Recombinant human parvovirus B19 vectors: erythroid cell-specific delivery and expression of transduced genes.Journal of Virology.  72:5224-5230. 1998
1998 Adeno-associated virus type 2-mediated gene transfer: correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo.Journal of Virology.  72:1593-1599. 1998
1997 Adeno-associated virus type 2-mediated transduction in primary human bone marrow-derived CD34+ hematopoietic progenitor cells: donor variation and correlation of transgene expression with cellular differentiation.Journal of Virology.  71:8262-8267. 1997
1997 Encapsidation of adeno-associated virus type 2 Rep proteins in wild-type and recombinant progeny virions: Rep-mediated growth inhibition of primary human cells.Journal of Virology.  71:7361-7371. 1997
1997 Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression.Proceedings of the National Academy of Sciences.  94:10879-10884. 1997
1997 Evaluation of recombinant adeno-associated virus as a gene transfer vector for the retina.Current Eye Research.  16:949-956. 1997
1997 Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice.Gene.  190:203-210. 1997
1997 Adeno-associated virus type 2 DNA replication in vivo: mutation analyses of the D sequence in viral inverted terminal repeats.Journal of Virology.  71:3077-3082. 1997
1997 Adeno-associated virus type 2-mediated transduction of murine hematopoietic cells with long-term repopulating ability and sustained expression of a human globin gene in vivo.Journal of Virology.  71:3098-3104. 1997
1997 Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cells.Human Gene Therapy.  8:275-284. 1997
1996 Differential expression in human cells from the p6 promoter of human parvovirus B19 following plasmid transfection and recombinant adeno-associated virus 2 (AAV) infection: human megakaryocytic leukaemia cells are non-permissive for AAV infection.Journal of General Virology.  77 ( Pt 6):1111-1122. 1996
1996 Rescue and replication of adeno-associated virus type 2 as well as vector DNA sequences from recombinant plasmids containing deletions in the viral inverted terminal repeats: selective encapsidation of viral genomes in progeny virions.Journal of Virology.  70:1668-1677. 1996
1996 Adeno-associated virus 2-mediated transduction and erythroid lineage-specific expression in human hematopoietic progenitor cells.Current Topics in Microbiology and Immunology.  218:93-117. 1996
1995 Cord blood transplantation and the potential for gene therapy. Gene transduction using a recombinant adeno-associated viral vector.Annals of the New York Academy of Sciences.  770:105-115. 1995
1995 Transcriptional transactivation of parvovirus B19 promoters in nonpermissive human cells by adenovirus type 2.Journal of Virology.  69:8096-8101. 1995
1995 Rescue and replication signals of the adeno-associated virus 2 genome.Journal of Molecular Biology.  250:573-580. 1995
1995 Mouse silver mutation is caused by a single base insertion in the putative cytoplasmic domain of Pmel 17.Nucleic Acids Research.  23:154-158. 1995
1994 Structural organization of the human tyrosinase gene and sequence analysis and characterization of its promoter region.Journal of Investigative Dermatology.  102:744-748. 1994
1994 Suppression of human alpha-globin gene expression mediated by the recombinant adeno-associated virus 2-based antisense vectors.Journal of Experimental Medicine.  179:733-738. 1994
1992 A cis-acting element involved in mouse tyrosinase gene expression and partial purification of its binding protein.Pigment Cell Research.  5:155-161. 1992
1992 Enzymes of the pentose phosphate pathway in glutathione-regulated membrane protection in beta-thalassaemia.European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.  30:481-484. 1992
1992 Amelioration of clinical severity through raised fetal hemoglobin in sickle cell anaemia.Indian Journal of Pediatrics.  59:85-90. 1992
1992 Enzymes of the pentose phosphate pathway in glutathione-regulated membrane protection in β-thalassaemiaEuropean journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.  30:481-484. 1992
1990 Elevated G gamma:A gamma globin chain ratio in homozygous beta thalassemia.Clinical Biochemistry.  23:529-531. 1990
1990 ElevatedGγ:Aγ globin chain ratio in homozygous beta thalassemiaClinical Biochemistry.  23:529-531. 1990
1989 Influence of gamma chains in in vitro globin synthesis in β° and β+homozygous thalassaemiaMedical Science Research.  17:409-410. 1989

Principal Investigator On

  • Targeted Therapy for Breast Cancer with Osteolytic Bone Damage  awarded by National Cancer Institute/NIH/DHHS 2015 - 2020
  • 1/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership - Pilot Project #2  awarded by National Cancer Institute/NIH/DHHS 2014 - 2019
  • Targeted Stem Cell Therapy Coupling Angiogenesis and Osteogenesis for Bone Defect  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2011 - 2019
  • Osteoimmune Mechanisms of Segmental Bone Fracture Healing and Therapy  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY 2015 - 2018
  • Gene-Engineered and Targeted Stem Cell Therapy for Myeloma  awarded by National Cancer Institute/NIH/DHHS 2009 - 2016
  • Regenerative Stem Cell Therapy for Breast Cancer Bone Metastasis  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY 2011 - 2015
  • rAAV Vaccine Vector  awarded by National Cancer Institute/NIH/DHHS 2008 - 2014
  • AAV-Mediated Gene Therapy for Metabolic Bone Disease  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2005 - 2012
  • UAB Core Center for Basic Skeletal Research  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2010 - 2012
  • UAB Core Center for Basic Skeletal Research - Core A  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2010 - 2012
  • AAV-Based Plasmacytoid Dentritic Cell Cancer Vaccine  awarded by CLEVELAND CLINIC FOUNDATION 2006 - 2011
  • Investigator On

  • Ga13 Signaling Attenuates Periodontal Inflammation and Alveolar Bone Loss in the Mouse Model of Age-Associated Periodontitis  awarded by National Institute of Dental and Craniofacial Research/NIH/DHHS 2018 - 2023
  • 3/3 Morehouse School of Medicine/Tuskegee University/University of Alabama Cancer Center Partnership  awarded by National Cancer Institute/NIH/DHHS 2016 - 2021
  • Morehouse School of Medicine/Tuskegee University/University of Alabama Cancer Center Partnership: (Admin Supplement) to Support Development of PDX at UAB CCC  awarded by National Cancer Institute/NIH/DHHS 2016 - 2021
  • Morehouse School of Medicine/Tuskegee University/University of Alabama Cancer Center Partnership: Project 1: CD24-Dependent Inactivation of Mutant p53 in Metastatic Castration-Resistant Prostate Cancer  awarded by National Cancer Institute/NIH/DHHS 2016 - 2021
  • 1/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership  awarded by National Cancer Institute/NIH/DHHS 2014 - 2019
  • Heparanase Regulation of Myeloma Metastasis: Mechanism and Therapy  awarded by National Cancer Institute/NIH/DHHS 2014 - 2019
  • Lumina III System for UAB Optical Imaging  awarded by NIH - OFFICE OF THE DIRECTOR 2016 - 2017
  • Morehouse School of Medicine/Tuskegee University/University of Alabama Cancer Center Partnership  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • A Specific Screening Strategy to Reduce Prostate Cancer Mortality  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY 2012 - 2015
  • Education And Training

  • Doctor of Philosophy in Genetics, University of Madras
  • Master's Level Degree in Genetics, University of Madras
  • Full Name

  • Selvarangan Ponnazhagan
  • Blazerid

  • pons